2025.04

Our CTO, Yuko Sekino (Project Professor at the University of Tokyo), will speak at CPHI Japan (Tokyo Big Sight) on “A Japan-Driven Breakthrough in MCI Treatment: Drebrin Drug Discovery from Memory Research.

2025.03

The Funakoshi website has been updated with new details on the anti-drebrin antibody, M2F6-Shirao.

2025.03

Our diagnostic project has been selected for AMED’s FY2025 Medical Device Development Promotion Research Program.

2025.01

We exhibited a booth at Japan Night held in San Francisco on January 13, 2025.

2024.11

AlzMed Products Now Available through Funakoshi – Featuring Drebrin Antibody and Frozen Rat Primary Hippocampal Neurons

2024.01

Our patent for an animal model of Alzheimer’s disease has been registered.

2023.08

Our patent on drdrebrin-binding peptide was registered.

2023.03

Our patent for a diagnostic agent has been registered.

2023.08

We have been selected for the Tokyo Metropolitan Small and Medium Enterprise Promotion Agency’s startup intellectual property support program.

2022.06

Presenting as the Japanese representative at the world’s largest startup competition, the Extreme Tech Challenge (XTC) World Finals